Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|25 CitationsCosmetic & Skin

Melanotan 2 Dosing Protocol: Tanning Research Guide

Also known as: MT-2, Melanotan II, Cyclic Alpha-MSH Analog

Dose Range
0.25 mgResearch range
0Typical research window: 0.25 mg0.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Loading Phase Protocol): 0.25 mg, Daily for first week, then every other day.

Protocol at a Glance
How Often
Daily

Daily for first week, then every other day

A Typical Run
2-3 weeks until desired tan achieved

Research-reported range; the linked study used a different dose or units. Tanning effects visible within 5 doses

How It's Taken
Vial

Subcutaneous

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 0.25 mg10 units

All U-100: 100 units = 1 mL. 20 doses in the vial at the low end.

Track the doses you run

Save Melanotan 2 (MT-2) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Melanotan 2 (MT-2) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$25.00 net$50.00
10mg Lyophilized Vial
$2.50/mg$5.00/mg retail
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$42.00
10mg vial
$4.20/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$43.99
10mg vial
$4.40/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$46.00
10mg vial
$4.60/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$65.00
10mg vial
$6.50/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$69.00
10mg vial
$6.90/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Central Melanocortin Receptor Agonist (MC1R / MC3R / MC4R)
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Melanocortin Agonist?

A compound that activates melanocortin receptors (MC1R-MC5R) in the body. These receptors control pigmentation, sexual arousal, appetite, and inflammation. PT-141 (Bremelanotide) activates MC4R for sexual function. Melanotan 2 activates MC1R for tanning. Both are synthetic analogs of alpha-MSH.

Bottom Line Up Front

Melanotan 2 is a synthetic melanocortin agonist that stimulates melanogenesis for UV-independent tanning. It also has aphrodisiac effects through MC4R activation. Not FDA approved. Long-term safety data is limited.

Best evidence for

UV-independent tanning, sexual arousal

Weakest evidence for

Skin cancer prevention (theoretical only)

Pharma equivalent

None

Studies on file

25 (15 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Melanotan 2 (MT-2) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Melanotan 2 is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis, the production of melanin in the skin. Originally developed as a sunless tanning agent and potential skin cancer preventative, it also has aphrodisiac effects through melanocortin receptor activation.

Mechanisms of Action

  • Binds to melanocortin receptors (MC1R) on melanocytes
  • Stimulates eumelanin production (brown/black pigment)
  • Activates MC4R receptors affecting appetite and sexual arousal
  • Provides UV-independent tanning

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Loading Phase Protocol
reported protocol
0.25 mgDaily for first week, then every other day2-3 weeks until desired tan achievedSubcutaneoushuman
Maintenance Protocol
reported protocol
0.5 mgTwice weeklyOngoingSubcutaneoushuman—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (Melanotan 2 (MT-2))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

15 Human10 Animal

Judicious use of protecting groups provides for chemoselective stapling using &#x3b1;-MSH, which provides a basis for investigating both chemoselectivity and affinity. Both classes of stapled peptides show nanomolar Ki's, with one showing a sub-nanomolar Ki value.

Limitations: Animal study only — human translation uncertain.

2024|Chemistry (Weinheim an der Bergstrasse, Germany)
PubMed

Animals fed a HF diet and treated with MT-II demonstrated recognition memory, anxiety, and exploratory behavior similar to the control group. This study provides evidence that even a short-term HF diet has an impact on memory and emotions and is the first study to show that MT-II reverses these changes.

Limitations: Animal study only — human translation uncertain.

2023|Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
PubMed

Enhanced sampling molecular dynamics simulations were found to be instrumental in outlining how the employed cyclization strategy affects the peptides' conformational behavior and, as a consequence, the detected hMC1R affinity. Additionally, a model of the peptide 5/hMC1R complex employing the very recently reported cryogenic electron microscopy receptor structure was provided.

Limitations: No placebo control reported.

2022|Journal of medicinal chemistry
PubMed

MT-II injected into the NAcc significantly decreased consumption in both home cage and operant paradigms, and furthermore decreased appetitive responding to gain access to food. There was no development of conditioned taste avoidance or change in metabolic parameters following anorexic doses of MT-II.

Limitations: Animal study only — human translation uncertain.

2022|Neuropeptides
PubMed

A total of 623 discussion entries were extracted; 205 participants contributed to these entries. Emergent themes included motivation for MT II use, misinformation in the context of using an unregulated product, product preparation and administration, dosing regimens, sunbed use, side effects and concerning practices associated with MT II use.

Limitations: No placebo control reported.

2022|Dermatology (Basel, Switzerland)
PubMed

We present a review of Melanotan II and the possible effects of this drug on the kidneys by including a case of a renal infarction most likely attributed to Melanotan II. In the mechanism of renal injury with Melanotan II, thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered.

Limitations: No placebo control reported. Review article — no new primary data.

2021|CEN case reports
PubMed

Based on the clinical distinction, we propose a new subclassification of EMN: (1) widespread eruptive nevi (WEN), with numerous small nevi, triggered by, for example, drugs and internal diseases, and (2) K&#xf6;bner-like eruptive nevi, often with big and few nevi, associated with skin diseases and most often localized at the site of previous skin disease/trauma. The nature of the data precluded assessment of risk of malignant transformation.

Limitations: No placebo control reported. Review article — no new primary data.

2020|American journal of clinical dermatology
PubMed

Acute priapism is an unreported side effect of melanocortin analogue use and this case report presents a patient managed without surgical intervention. Future therapeutic application of these agents will need to take this potential life altering complication into consideration.

Limitations: No placebo control reported. Review article — no new primary data.

2019|BMJ case reports
PubMed

Additionally, there was no change in anxiety-like or repetitive behaviors following MT-II treatment of normal C57 mice, though there was significant weight loss following subacute treatment. These data demonstrate MT-II as an effective agent for improving autism-like behavioral deficits in the adult male MIA mouse model of autism.

Limitations: Animal study only — human translation uncertain.

2019|PloS one
PubMed

Likewise, the participation of MTs in other neurological disorders has also been reported. This review shows recent evidence about the role of MT in the central nervous system and its possible role in neurodegenerative diseases as well as in brain disorders.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2018|Oxidative medicine and cellular longevity
PubMed

An observational survey was posted to an online forum in which participants share their experiences using melanotan-I or melanotan-II. Users were asked to complete this voluntary, anonymous survey, which had questions focusing on motivation and hesitation for and against using melanotan, difficulty in acquiring it, and plans for continuing to use melanotan in the future.

Limitations: No placebo control reported.

2018|Dermatology online journal
PubMed

Consistent with this finding, intraventricular administration of melanotan-2, an analog of the POMC derivative &#x3b1;-MSH, suppressed adult obesity in Gpr45 mutants. These results reveal that GPR45 is a regulator of POMC signaling and energy expenditure, which suggests that it may be a potential intervention target to combat obesity.

Limitations: Animal study only — human translation uncertain.

2017|The Journal of clinical investigation
PubMed

In fact, the proteolytic stable 1,4- or 4,1-disubstituted [1,2,3]triazolyl moiety is isosteric with the peptide bond and can function as a surrogate of the classical side chain-to-side chain lactam forming bridge. Herein we report the design, synthesis, conformational analysis, and functional biological activity of a series of i-to-i+5 1,4- and 4,1-disubstituted [1,2,3]triazole-bridged cyclopeptides derived from MT-II, the homodetic Asp(5) to Lys(10) side chain-to-side chain bridged heptapeptide, an extensively studied agonist of melanocortin receptors.

Limitations: No placebo control reported.

2015|Journal of medicinal chemistry
PubMed

As the drug is unlicensed and incompletely tested, the extent and types of adverse effects are unknown. Clinicians are advised to be aware of the problem, and counsel their at-risk patients regarding the potential hazards related to the use of MT-II.

Limitations: No placebo control reported.

2014|Dermatology (Basel, Switzerland)
PubMed

Melanotan-associated melanoma. (The British journal of dermatology, 2012)

Limitations: No placebo control reported. Case study — cannot establish causation.

2012|The British journal of dermatology
PubMed

[Melanotan].

Human Study

[Melanotan]. (Actas dermo-sifiliograficas, 2012)

Limitations: No placebo control reported.

2012|Actas dermo-sifiliograficas
PubMed

Use of melanotan I and II in the general population. (BMJ (Clinical research ed.), 2009)

Limitations: No placebo control reported.

2009|BMJ (Clinical research ed.)
PubMed

In conscious rats, MT-II (1 mg/kg) significantly increased overall erectile activity compared to saline. In anesthetized rats, MT-II-induced increase in overall erectile activity was not statistically significant but displayed a similar pattern.

Limitations: Animal study only — human translation uncertain.

2005|European urology
PubMed

By contrast, only one key trans-activating factor, namely MTF-1, has been extensively characterized. Studies on the epigenetic silencing of MT-I and MT-II by promoter hypermethylation in some cancer cells have posed interesting questions concerning the functional relevance of MT gene silencing, the molecular mechanisms of MT suppression in these cells, particularly chromatin modifications, and the characteristics of the repressors.

Limitations: No placebo control reported. Review article — no new primary data.

2000|Progress in nucleic acid research and molecular biology
PubMed

Exposure of these habituated mice to a different type of stress (treatment with heavy metals such as cadmium or zinc sulfate) led to further MT induction. Because heavy metals induced MT via activation of the factor MTF-1, distinct molecular mechanisms should be responsible for the activation of MT promoter by different inducers.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

1999|Gene expression
PubMed

Discovery and development of novel melanogenic drugs. Melanotan-I and -II. (Pharmaceutical biotechnology, 1998)

Limitations: No placebo control reported. Review article — no new primary data.

1998|Pharmaceutical biotechnology
PubMed

The expression of MT-II gene by zinc is regulated through activation of the zinc regulatory factor (ZRF). MT-III, a brain-specific isoform, plays a role in preventing neuronal sprouting and in the repair after brain damage.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

1997|Journal of UOEH
PubMed

Studies demonstrating that MT-III prevents neuronal sprouting in vitro, appears to be down-regulated in Alzheimer's disease, and that MT-III "knockout" mice appear highly sensitive to kainateinduced seizures have focused growing attention on the etiologic role of MT-III in neurodegeneration.-Aschner, M. The functional significance of brain metallothioneins.

Limitations: No placebo control reported. Review article — no new primary data.

1996|FASEB journal : official publication of the Federation of American Societies for Experimental Biology
PubMed

The presence of even one aberrant data point in the beta-phase can significantly influence t1/2 beta when only a few data points are available in the beta-phase. Since MRT and Vss were calculated from t1/2 beta it is not surprising that these two parameters also differed between methods.

Limitations: Animal study only — human translation uncertain.

1995|Biopharmaceutics &amp; drug disposition
PubMed

In both MT-I and MT-II processed genes these direct repeats towards the 5' end of the gene start with an AhaIII (TTTAAA) restriction site. Our studies suggest that these direct repeats are the results of the insertion site duplication.

Limitations: No placebo control reported.

1985|Gene
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Not FDA approved for any indication
  • •May cause darkening of existing moles and freckles
  • •Nausea and facial flushing common
  • •Spontaneous erections reported (dose-dependent)
  • •Long-term safety data limited
  • •May stimulate melanoma risk (theoretical concern)
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Melanotan 2 (MT-2), baseline labs & clinician oversight.

Full Melanotan 2 (MT-2) $/mg comparison →
50% OFF AUTO-APPLIED$2.50/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Melanotan 2 (MT-2): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $2.50/mg (10mg Lyophilized Vial, $25.00)
  2. 2. Elite Research USA — $4.20/mg (10mg vial, $42.00)
  3. 3. Swift Peptides — $4.40/mg (10mg vial, $43.99)

Where is the cheapest place to buy Melanotan 2 (MT-2)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $2.50/mg (10mg Lyophilized Vial, $25.00 after the 50% new-customer partner-link discount). We compared 6 US suppliers with live, checked prices.

How much does Melanotan 2 (MT-2) cost per mg?

Verified US domestic prices currently range from $2.50/mg to $6.90/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Melanotan 2 (MT-2) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.